Congress trades and big insider sales, sent the day they're filed. Free.
Open in TelegramOfficers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 2 | Krupka Devin MController, PAO | Option exercise | M | — 2,775 sh | Sep 1, 2026 |
| 2 | Wittmann MichaelChief Operating Officer | Grant or award | A | — 33.0K sh | Sep 1, 2026 traded Aug 28, 2026 |
| 2 | Wittmann MichaelChief Operating Officer | Option exercise | M | — 6,250 sh | Sep 1, 2026 traded Aug 31, 2026 |
| 2 | Ross KadeChief Information Officer | Option exercise | M | — 1,853 sh | Sep 1, 2026 traded Aug 28, 2026 |
| 2 | Agarwal DeveshChief Operating Officer | Option exercise | M | — 2,086 sh | Sep 1, 2026 traded Aug 28, 2026 |
| 2 | Ross KadeChief Information Officer | Option exercise | M | — 446 sh | Sep 1, 2026 traded Aug 28, 2026 |
| 2 | Wittmann MichaelChief Operating Officer | Option exercise | M | — 33.0K sh | Sep 1, 2026 traded Aug 28, 2026 |
| 2 | Ross KadeChief Information Officer | Option exercise | M | — 446 sh | Sep 1, 2026 traded Aug 28, 2026 |
| 2 | Ross KadeChief Information Officer | Option exercise | M | — 3,392 sh | Sep 1, 2026 traded Aug 28, 2026 |
| 2 | Sousa Mauad BrunoDirector | Derivative conversion | C | $33K 1,168 sh | Sep 1, 2026 traded Aug 28, 2026 |
| 1 | Hansen GwennChief Scientific Officer | Open-market sale · 10b5-1 plan | SELL | $37K 1,452 sh | Sep 1, 2026 traded Sep 1, 2026 |
| 0 | Hansen GwennChief Scientific Officer | Option exercise · 10b5-1 plan | M | — 1,452 sh | Sep 1, 2026 traded Sep 1, 2026 |
| 0 | Hansen GwennChief Scientific Officer | Option exercise · 10b5-1 plan | M | $2,701 1,452 sh | Sep 1, 2026 traded Sep 1, 2026 |
| 0 | Cieri MichaelChief Product Officer | Option exercise · 10b5-1 plan | M | — 12.9K sh | Sep 1, 2026 traded Aug 28, 2026 |
| 0 | Doyle MittieChief Medical Officer | Option exercise · 10b5-1 plan | M | — 679 sh | Sep 1, 2026 traded Aug 28, 2026 |
| 0 | Jain RohiniChief Financial Officer | Option exercise · 10b5-1 plan | M | — 50.3K sh | Sep 1, 2026 traded Aug 28, 2026 |
| 0 | Doyle MittieChief Medical Officer | Option exercise · 10b5-1 plan | M | $5,459 679 sh | Sep 1, 2026 traded Aug 28, 2026 |
| 0 | Britt Christopher RDirector, Chief Executive Officer | Derivative conversion · 10b5-1 plan | C | — 88.6K sh | Sep 1, 2026 traded Aug 28, 2026 |
| 0 | Hamilton Brian TDirector, President of CCBX | Tax withholding · 10b5-1 plan | F | $11K 232 sh | Sep 1, 2026 traded Sep 1, 2026 |
| 56 | Schuetz Arthur Josef HermannCFO Schmid Group N.V. | Open-market purchase | BUY | $49K 15.2K sh | Aug 31, 2026 traded Aug 28, 2006 |
| 50 | Laughton Mary BethDirector | Open-market sale | SELL | $515K 10.2K sh | Aug 31, 2026 traded Aug 27, 2026 |
| 48 | Schlosser MarioDirector | Open-market sale | SELL | $18.20M 600.0K sh | Aug 31, 2026 traded Aug 27, 2026 |
| 46 | Antz Christoph RudigerDirector, Chief Executive Officer | Open-market purchase | BUY | $7,650 5,000 sh | Aug 31, 2026 traded Aug 27, 2026 |
| 45 | Jaros Carey F.Director | Open-market purchase | BUY | $176K 15.0K sh | Aug 31, 2026 traded Aug 27, 2026 |
| 44 | Gibson Dwight Audley KonradDirector | Open-market purchase | BUY | $244 5 sh | Aug 31, 2026 traded Aug 27, 2026 |
| 44 | Agress Adam LEVP Business Development | Open-market sale | SELL | $6,654 1,784 sh | Aug 31, 2026 traded Aug 27, 2026 |
| 44 | Corrado Felipe Amilcar IVInterim CEO & CFO | Open-market purchase | BUY | $960 4,000 sh | Aug 31, 2026 traded May 23, 2025 |
| 44 | Courtney Mark RVice President of Supply Chain | Open-market sale | SELL | $3,297 884 sh | Aug 31, 2026 traded Aug 27, 2026 |
| 41 | Schlosser MarioDirector | Open-market sale | SELL | $4.62M 150.0K sh | Aug 31, 2026 traded Aug 28, 2026 |
| 40 | Orebaugh Chad ThomasEVP of Engineering | Open-market sale | SELL | $5,528 1,482 sh | Aug 31, 2026 traded Aug 27, 2026 |
| 40 | Knaggs David H.EVP of Quality and IS | Open-market sale | SELL | $5,528 1,482 sh | Aug 31, 2026 traded Aug 27, 2026 |
| 40 | Voorhees Anthony GeneEVP-Admin, CFO, Treasurer | Open-market sale | SELL | $8,400 2,252 sh | Aug 31, 2026 traded Aug 27, 2026 |
| 38 | Chamberlain Paul EdwardDirector | Open-market sale | SELL | $167K 2,400 sh | Aug 31, 2026 traded Aug 27, 2026 |
| 37 | Baumann Oliver RolfDirector | Open-market purchase | BUY | $75K 50.0K sh | Aug 31, 2026 traded Aug 27, 2026 |
| 37 | Calvert Christopher PEVP and CFO | Open-market purchase | BUY | $142K 2,500 sh | Aug 31, 2026 traded Aug 27, 2026 |
| 37 | Schmid AnetteDirector, 10% Owner | Open-market purchase | BUY | $218K 69.0K sh | Aug 31, 2026 traded Aug 30, 2026 |
| 36 | Sayad Pierre SargisChief Medical Officer | Open-market sale | SELL | $146K 12.0K sh | Aug 31, 2026 traded Aug 31, 2026 |
| 36 | Peterson Carol R.Director | Grant or award | A | — 71.8K sh | Aug 31, 2026 traded Jun 3, 2026 |
| 34 | Eddy ShalevDirector | Open-market sale | SELL | $3.09M 99.1K sh | Aug 31, 2026 traded Aug 28, 2026 |
| 34 | Jaros Carey F.Director | Other acquisition or disposition | J | — 45.0K sh | Aug 31, 2026 traded Jul 30, 2026 |